Back to Search
Start Over
Lilly's new heart drug skips a beat
- Source :
- Barron's. Nov 19, 2007, Vol. 87 Issue 47, p23, 2 p.
- Publication Year :
- 2007
-
Abstract
- Eli Lilly's P rasugrel heart drug had mixed test results but the drug will still go to market because it prevented more incidents of heart attack than added bleeding. The company's shares could drop another 10% if the product fails to generate sales especially since the company has no other pot ential blockbuster product in development and some of their patents will expire by 2011 .
- Subjects :
- Eli Lilly and Co. -- Product development
Eli Lilly and Co. -- Securities
Eli Lilly and Co. -- Company forecasts
Drugs -- Testing
Drugs -- Marketing
Drugs -- Complications and side effects
Pharmaceutical industry -- Product development
Pharmaceutical industry -- Securities
Pharmaceutical industry -- Company forecasts
Company securities
Company business forecast/projection
Company marketing practices
Banking, finance and accounting industries
Business
Prasugrel (Medication) -- Testing
Prasugrel (Medication) -- Marketing
Prasugrel (Medication) -- Complications and side effects
Subjects
Details
- Language :
- English
- ISSN :
- 10778039
- Volume :
- 87
- Issue :
- 47
- Database :
- Gale General OneFile
- Journal :
- Barron's
- Publication Type :
- Periodical
- Accession number :
- edsgcl.173077810